Activation of Wnt signaling, observed in tumor samples through the methylation of SFRP5 gene, could cause tumor resistance to EGFR TKIs and, on account of this it was associated with poorer treatment outcomes [62]. The gene discussed is EGFR; the disease is neoplasm.